Clinical Trial to Study Impact of ActivePure Technology on Surgical Site Infections

Dec. 16, 2020 20:33 UTC

 

 
 

DALLAS--(BUSINESS WIRE)-- Aerus Medical formally announced the start of a double-blind two-year clinical study to evaluate the impact the Aerus Medical Guardian with ActivePure Technology can have on reducing nosocomial infections, or healthcare-associated infections, also known as HAIs, from surgical operating room procedures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005947/en/

Aerus Medical Guardian with ActivePure Technology reduces bacteria and viruses in the air by 99.99% within 30 minutes and surface contamination by more than 99% after several hours. (Photo: Business Wire)

Aerus Medical Guardian with ActivePure Technology reduces bacteria and viruses in the air by 99.99% within 30 minutes and surface contamination by more than 99% after several hours. (Photo: Business Wire)

Aerus Medical Guardian with ActivePure Technology, a U.S. FDA Class II Medical Device, reduces bacteria and viruses in the air by 99.99% within 30 minutes and surface contamination by more than 99% after several hours. The primary goal of the randomized trial will be to determine whether filtering and sterilizing operating room air with the Aerus Medical Guardian with ActivePure Technology air purifier reduces a composite of serious surgical site infections, infection-related complications, and death within 30 days after surgery. Secondarily, the trial will determine the effect of air filtration and sterilization on serious surgical site infections and on the cost of care.

HAIs are a significant concern that can have serious medical, emotional, and financial consequences. These types of infections cost the U.S. healthcare system billions of dollars each year. According to the Centers for Disease Control and Prevention, on any given day, about one in 31 hospital patients has at least one HAI.

The Aerus Medical Study will use 50 noncardiac, adult operating rooms at Cleveland Clinic. The trial will be restricted to adults aged 18 years or older, having surgery lasting at least one hour. Patients with present-on-admission infections will be excluded from the study. Operating rooms will be randomized in one-month blocks to Aerus air sterilization or conventional air handling. A minimum of 67,653 patients with a maximum of 86,639 patients will be needed for this study.

The trial is expected to begin this year and last approximately two years.

The Aerus Medical Guardian with ActivePure Technology is roughly the size and configuration of carry­on luggage (26.5″H x 11.5″W x 21.0″D) and weighs 48 pounds. It cleans 18,000 cubic feet of air per hour on its “high” setting. The system actively cleans the air with activated carbon, ActivePure Molecules, and high-efficiency particulate filtration.

The Aerus Medical study is sponsored by Aerus Medical LLC, the company that developed the surface and air purification unit Aerus Medical Guardian with ActivePure Technology.

ABOUT ACTIVEPURE TECHNOLOGY:

ActivePure Technologies, LLC is the global leader in active, continuous surface and air purification systems for health care, education, commercial and public facilities, hospitality and residential applications. ActivePure Technologies, LLC is the exclusive worldwide owner of patented ActivePure Technology, the most powerful surface and air purification technology ever discovered, and the only one in its class recognized by the Space Foundation as Certified Space Technology and inducted into the Space Foundation Hall of Fame in 2017. ActivePure Technology has been engineered based on technology originally developed by NASA. Evolving from early-stage NASA designs, ActivePure Technology quickly, proactively and continuously minimizes the number of contaminants on all indoor surfaces and in the air. The systems produce sub-microscopic hydroxyls and ions, ActivePure Molecules, that destroy contaminants on contact, reducing exposure to diseases, including RNA and DNA viruses, bacteria and mold. Independent scientific data repeatedly shows that the patented ActivePure Technology is the most powerful air and surface purification solution ever discovered, reducing over 99% of surface microorganisms and airborne contaminants. The ActivePure badge, displayed across the world, provides peace of mind that there is continuous 24/7 surface and air protection in the indoor space. In 2020, the Aerus Medical Guardian, with ActivePure, was registered and cleared as an FDA Class II Medical Device. Unlike many other technologies, ActivePure is safe to use in indoor spaces while occupied by people - quickly, continuously, and safely reducing exposure to pathogens. Patented ActivePure Technology is designed, engineered and manufactured in the U.S. and is a division of ActivePure Technologies, LLC. For more information, please visit ActivePure.com or AerusMedical.com.

Contacts

Jo Trizila, TrizCom PR on behalf of ActivePure Technologies, LLC
Email: Jo@TrizCom.com
Office: 972-247-1369
Cell/Text: 214-232-0078

Ann Littmann, TrizCom PR on behalf of ActivePure Technologies, LLC
Email: Ann@TrizCom.com
Office: 972-247-1369
Cell/Text: 469-978-1793

 
 

Source: ActivePure Technologies, LLC

Smart Multimedia Gallery

Aerus Medical Guardian with ActivePure Technology reduces bacteria and viruses in the air by 99.99% within 30 minutes and surface contamination by more than 99% after several hours. (Photo: Business Wire)

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20201216005947/en

Back to news